News

Participants in the Phase 3, open-label extension study, B-YOND, maintained low bleeding rates with one to two week prophylaxis regimens, according to data from an interim analysis. Investigators

Xilonix, a novel anti-cancer agent, is being developed via a ground-breaking regulatory path that XBiotech established in collaboration with the scientific advisory committee of the European Medicines Agency

Octreotide capsules, an oral drug, are indicated for the maintenance therapy of adult patients with acromegaly. The agency has assigned a Prescription Drug User Fee Act (PDUFA) date

Conducted in collaboration with the University of Halle as sponsor and with the participation of two large leukemia study groups in Germany, the trial is aimed at evaluating

The agency has assigned a Prescription Drug User Fee Act (PDUFA) action date of 10 April 2016 for BromSite, which has a long patent life extending to August

The agency has assigned a Prescription Drug User Fee Act (PDUFA) goal date of 01 April 2016 for a decision on this NDA and it reflects a Standard

The acquisition now expands the company’s suite of maternal health business and adds improved commercial capabilities as well as future growth opportunities to its portfolio. Currently, CBR’s storage

The contract with the Biomedical Advanced Research and Development Authority (BARDA) will fund activities related to current Good Manufacturing Practice (cGMP) manufacturing of a drug product and a

The focus of the collaboration, originally signed in 2014, is the development and validation of HiFiBiO’s proprietary, high throughput antibody discovery platform for deep mining of immune repertoires.